HB 2162 Modifies provisions relating to Opioid Addiction Treatment

     Handler: Hegeman

Current Bill Summary

- Prepared by Senate Research -

SS/HB 2162 - Under this act, the Director of the Department of Health and Senior Services, if a licensed physician, or a licensed physician on behalf of the Director, may issue a statewide standing order for an addiction mitigation medication, defined as naltrexone hydrochloride administered in a manner approved by the U.S. Food and Drug Administration or any accepted medical practice method of administering.

Any licensed pharmacist may sell and dispense an addiction mitigation medication under a physician protocol or a statewide standing order. A pharmacist who, acting in good faith and with reasonable care, sells or dispenses the addiction mitigation medication and an appropriate device to administer the drug, and the protocol physician, shall not be subject to any criminal or civil liability or professional disciplinary action for prescribing or dispensing the medication and any outcome resulting from the administration of the medication. A physician issuing the statewide standing order shall likewise face no liability or professional discipline relating to the order or administration of the medication.

It shall be permissible for any person to possess an addiction mitigation medication.

This provision is identical to provisions in the truly agreed to and finally passed SS/SCS/HB 2331 (2022), CCS/HCS/SS/SB 690 (2022), SB 1037 (2022), and HB 2603 (2022).

This act modifies the Opioid Addiction Treatment and Recovery Fund to permit the Department of Corrections and the judiciary to access moneys in the fund for the purposes of opioid addiction treatment and prevention services and health care and law enforcement costs related to opioid addiction treatment and prevention.

This provision is substantially similar to SB 1032 (2022).


Go to Main Bill Page  |  Return to Summary List  |  Return to Senate Home Page